3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
31
Recurrence
4
Renal Insufficiency
1
Kidney Failure, Chronic
1
Immunoglobulin Light-chain Amyloidosis
1
Amyloidosis
1
Interventions
Dexamethasone
6
birtamimab
5
Bortezomib
4
miridesap
3
Cyclophosphamide
3
Clinical Protocols
2
melflufen
1
ixazomib
1
daratumumab
1
belantamab mafodotin
1
Fentanyl
1
Drug Evaluation
1
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immunoglobulin Light-chain Amyloidosis
×
belantamab mafodotin
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled